活動性ループス腎炎クラス III-IV、+/- V の参加者における LNP023 の有効性と安全性の研究
適応型、無作為化、二重盲検、用量調査、並行群間、プラセボ対照、多施設第 2 相試験で、活動性狼瘡患者における経口コルチコステロイドの有無にかかわらず、標準治療と組み合わせた LNP023 の有効性、安全性、忍容性を評価腎炎 クラス III~IV、+/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
調査の概要
状態
条件
詳細な説明
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90095
- Ronald Reagan UCLA Medical Center
-
San Bernardino、California、アメリカ、92408
- Loma Linda University
-
Sylmar、California、アメリカ、91342
- Olive View UCLA Medical Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Denver
-
-
Florida
-
Hollywood、Florida、アメリカ、33021
- Royal Research Corp
-
Orlando、Florida、アメリカ、32806
- Nephrology Associates Of Central FL
-
Riverview、Florida、アメリカ、33578
- Florida Kidney Physicians
-
-
Illinois
-
Hinsdale、Illinois、アメリカ、60521
- Nep Assoc of Northern Illinois
-
-
Kansas
-
Wichita、Kansas、アメリカ、67214
- Wichita Community Clcl Onco Program
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Health System
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins Hospital
-
-
New York
-
East Setauket、New York、アメリカ、11733
- Stony Brook Internists PC
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19140
- Temple University
-
-
Texas
-
Dallas、Texas、アメリカ、75204
- Dallas Nephrology Associates
-
Houston、Texas、アメリカ、77054
- Prolato Clinical Research Center
-
-
-
-
-
Santa Fe、アルゼンチン、S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Cambridge、イギリス、CB2 0QQ
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode、Kerala、インド、673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、インド、110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad、Telangana、インド、500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow、Uttar Pradesh、インド、226014
- Novartis Investigative Site
-
-
-
-
-
Montería、コロンビア、230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla、Atlántico、コロンビア、080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota、Cundinamarca、コロンビア、111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga、Santander Department、コロンビア、680003
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore、Singapore、シンガポール、308433
- Novartis Investigative Site
-
-
-
-
-
Barcelona、スペイン、08036
- Novartis Investigative Site
-
Ciudad Real、スペイン、13005
- Novartis Investigative Site
-
Madrid、スペイン、28034
- Novartis Investigative Site
-
Madrid、スペイン、28040
- Novartis Investigative Site
-
Seville、スペイン、41009
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul、Fatih、トルコ(Türkiye)、34093
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri、Melikgazi、トルコ(Türkiye)、38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa、Nilufer、トルコ(Türkiye)、16059
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara、Yenimahalle、トルコ(Türkiye)、06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin、Yenisehir、トルコ(Türkiye)、33110
- Novartis Investigative Site
-
-
-
-
-
Mainz、ドイツ、55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig、Lower Saxony、ドイツ、38126
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、ドイツ、51109
- Novartis Investigative Site
-
-
-
-
-
Budapest、ハンガリー、1083
- Novartis Investigative Site
-
Szeged、ハンガリー、6725
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen、Hajdu Bihar Megye、ハンガリー、4032
- Novartis Investigative Site
-
-
-
-
-
Quezon、フィリピン、1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City、National Capital Region、フィリピン、1218
- Novartis Investigative Site
-
-
-
-
-
Marseille、フランス、13005
- Novartis Investigative Site
-
Nantes、フランス、44093
- Novartis Investigative Site
-
-
-
-
-
Salvador、ブラジル、40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、ブラジル、30150-221
- Novartis Investigative Site
-
Juiz de Fora、Minas Gerais、ブラジル、36010-570
- Novartis Investigative Site
-
-
São Paulo
-
Barretos、São Paulo、ブラジル、14784-400
- Novartis Investigative Site
-
São Paulo、São Paulo、ブラジル、05403-000
- Novartis Investigative Site
-
São Paulo、São Paulo、ブラジル、04038-002
- Novartis Investigative Site
-
São Paulo、São Paulo、ブラジル、01308-050
- Novartis Investigative Site
-
-
-
-
-
San Juan、プエルトリコ、00927
- FDI Clinical Research
-
-
-
-
-
Carnaxide、ポルトガル、2799-523
- Novartis Investigative Site
-
Coimbra、ポルトガル、3004-561
- Novartis Investigative Site
-
Lisbon、ポルトガル、1649-035
- Novartis Investigative Site
-
Vila Nova de Gaia、ポルトガル、4434-502
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan、マレーシア、68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan、Pahang、マレーシア、25100
- Novartis Investigative Site
-
-
Perak
-
Taiping、Perak、マレーシア、34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes、メキシコ、20230
- Novartis Investigative Site
-
Veracruz、メキシコ、91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico、Tamaulipas、メキシコ、89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida、Yucatán、メキシコ、97070
- Novartis Investigative Site
-
-
-
-
-
Beijing、中国、100034
- Novartis Investigative Site
-
Shenzhen、中国、518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning、Guangxi、中国、530022
- Novartis Investigative Site
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang、Liaoning、中国、110004
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan、Ningxia、中国、750004
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong、Hong Kong、香港、999077
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
他の名前:
|
|
プラセボコンパレーター:Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
アクティブコンパレータ:Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
他の名前:
|
|
アクティブコンパレータ:Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
他の名前:
|
|
アクティブコンパレータ:Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
時間枠:Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
時間枠:Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
時間枠:Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
時間枠:Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
時間枠:Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
時間枠:Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
時間枠:Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
時間枠:Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CLNP023K12201
- 2021-002046-33 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。